Suppr超能文献

遗传性血管性水肿血浆中的通透性增加活性。II. 形成机制及部分特性

Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization.

作者信息

Donaldson V H, Ratnoff O D, Dias Da Silva W, Rosen F S

出版信息

J Clin Invest. 1969 Apr;48(4):642-53. doi: 10.1172/JCI106022.

Abstract

Plasma from persons with hereditary angioneurotic edema readily developed the capacity to increase vascular permeability and to induce the isolated rat uterus to contract. Both activities resided in a small, heat-stable molecule that was apparently a polypeptide. Crude preparations of the polypeptide were inactivated during incubation with trypsin. They also failed to produce pain and erythema, but caused markedly increased vascular permeability in human skin. These characteristics differ from those of bradykinin, from which crude preparations of the polypeptide could also be distinguished by electrophoretic mobility and paper chromatographic behavior. Proof that the polypeptide is truly different from bradykinin must await its further purification. Histamine played no role in the activities observed. Although the enzymes functioning to release the permeability factor and kinin activities in hereditary angioneurotic edema plasma were not clearly defined, one or more plasma enzymes other than C'1 esterase presumably participated either in conjunction with C'1 esterase or in pari passu events to release the polypeptide mediating these activities.

摘要

遗传性血管性水肿患者的血浆很容易产生增加血管通透性以及诱导离体大鼠子宫收缩的能力。这两种活性都存在于一种小的、热稳定的分子中,该分子显然是一种多肽。该多肽的粗制品在与胰蛋白酶孵育期间会失活。它们也不会产生疼痛和红斑,但会导致人体皮肤血管通透性显著增加。这些特性与缓激肽不同,该多肽的粗制品在电泳迁移率和纸层析行为方面也与缓激肽不同。要证明该多肽确实与缓激肽不同,必须等待其进一步纯化。组胺在观察到的活性中不起作用。尽管在遗传性血管性水肿血浆中发挥作用以释放通透性因子和激肽活性的酶尚未明确界定,但除C'1酯酶外,一种或多种血浆酶可能与C'1酯酶协同作用,或者在同等事件中参与释放介导这些活性的多肽。

相似文献

引用本文的文献

1
The Story of Angioedema: from Quincke to Bradykinin.血管性水肿的故事:从昆克到缓激肽。
Clin Rev Allergy Immunol. 2016 Oct;51(2):121-39. doi: 10.1007/s12016-016-8553-8.
2
The pathophysiology of hereditary angioedema.遗传性血管性水肿的病理生理学。
World Allergy Organ J. 2010 Sep;3(9 Suppl):S25-8. doi: 10.1097/WOX.0b013e3181f3f21c.
3
The new era of C1-esterase inhibitor deficiency therapy.C1 酯酶抑制剂缺乏症治疗的新时代。
Curr Allergy Asthma Rep. 2011 Oct;11(5):345-51. doi: 10.1007/s11882-011-0213-8.
4
HAE therapies: past present and future.遗传性血管性水肿治疗:过去、现在与未来。
Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):23. doi: 10.1186/1710-1492-6-23.
6
C1 inhibitor: molecular and clinical aspects.C1 抑制剂:分子与临床方面
Springer Semin Immunopathol. 2005 Nov;27(3):286-98. doi: 10.1007/s00281-005-0001-4. Epub 2005 Nov 11.
8
IgA nephropathy in hereditary angioedema.遗传性血管性水肿中的IgA肾病
Postgrad Med J. 1993 Feb;69(808):95-9. doi: 10.1136/pgmj.69.808.95.

本文引用的文献

5
Assay and properties of serum inhibitor of C'l-esterase.C1酯酶血清抑制剂的测定与特性
Proc Soc Exp Biol Med. 1959 Aug-Sep;101:608-11. doi: 10.3181/00379727-101-25034.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验